Search results
- Use of triple therapy resulted in a lower rate of moderate or severe exacerbations of COPD, better lung function, and better health related quality of life than dual therapy or monotherapy in patients with advanced COPD.
People also ask
Should obstructive pulmonary disease be treated with triple therapy?
Does triple therapy improve lung function in patients with advanced COPD?
Is triple therapy better than dual therapy for COPD?
Does triple therapy increase the risk of pneumonia in patients with COPD?
Nov 6, 2018 · Use of triple therapy resulted in a lower rate of moderate or severe exacerbations of COPD, better lung function, and better health related quality of life than dual therapy or monotherapy in patients with advanced COPD.
- Yayuan Zheng, Jianhong Zhu, Yuyu Liu, Weiguang Lai, Chunyu Lin, Kaifen Qiu, Junyan Wu, Weimin Yao
- 10.1136/bmj.k4388
- 2018
- BMJ. 2018; 363: k4388.
Jul 5, 2021 · Most double-blind, international multicenter, randomized controlled trials of triple therapy have shown to lead to a lower risk of COPD exacerbation, a greater reduction in symptoms, a slower disease progression, better lung function and a promising signal of reduced all-cause mortality than dual therapies as shown in Supplementary Table 1. [4 –...
- Yong-Hua Gao, Rong-Chang Chen
- 2021
Aug 28, 2023 · Role of triple therapy in chronic obstructive pulmonary disease (COPD) management is supported by growing evidence, but consensus is lacking on various aspects. We conducted a Delphi survey in respiratory experts on the effects of triple therapy on exacerbation reduction, early optimization, pneumonia risk, and mortality benefits in COPD ...
- 10.2147/COPD.S424128
- 2023
- Time to First Exacerbation
- Lung Function
- Quality of Life
- Safety
In the TRINITY, TRILOGY and IMPACT studies the time to first moderate or severe exacerbation was significantly extended with triple therapy compared with LAMA/LABA, LABA/ICS and LAMA (Fig. 4). In the KRONOS study, the time to first moderate or severe exacerbation was extended with triple therapy; the improvement was significant with LAMA/LABA (haza...
In the three studies that assessed the single-inhaler triple therapy GLY/FOR/BDP (TRINITY, TRILOGY and TRIBUTE), triple therapy resulted in a significant change from baseline in pre-dose FEV1 compared with LAMA (61 mL; 95% CI: 37, 86; p < 0.0001 [52-week data]) , LABA/ICS (81 mL; 95% CI: 52, 109; p < 0.001 [26-week data], 63 mL; 95% CI: 32, 94; p <...
Across all the studies quality of life was assessed using the St. George’s Respiratory Questionnaire (SGRQ) . In the three studies that assessed the single-inhaler triple therapy GLY/FOR/BDP (TRINITY, TRILOGY and TRIBUTE), triple therapy resulted in greater improvement in SGRQ total score compared with TIO (at all timepoints except week 26 [weeks 4...
Across all the studies, SAEs were comparable between triple therapy and comparators. In the three studies that assessed the triple therapy GLY/FOR/BDP (TRINITY, TRILOGY and TRIBUTE), triple therapy was associated with a similar percentage of patients who experienced SAEs (13 –15% [17, 23]) compared with TIO (15%) , LABA/ICS (18%) and LAMA/LABA (17...
- Sue Langham, Jen Lewis, Nick Pooley, Nina Embleton, Julia Langham, MeiLan K. Han, James D. Chalmers
- 2019
Jul 5, 2021 · The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020 [2] recommends triple therapy only as a step-up from LAMA/LABA or LABA/ICS in patients who develop further exacerbations and have predominant symptoms of breathlessness while on maintenance therapy.
Does regular pharmacological treatment including inhaled corticosteroids (ICS) reduce mortality in patients with chronic obstructive pulmonary disease (COPD)?
Nov 6, 2018 · Objective: To compare the rate of moderate to severe exacerbations between triple therapy and dual therapy or monotherapy in patients with chronic obstructive pulmonary disease (COPD). Design: Systematic review and meta-analysis of randomised controlled trials.
